Streetbeat News

Earnings

ATMU

Atmus Filtration Techs (NYSE:ATMU) has received updated analyst ratings, with a consensus leaning towards 'Somewhat Bullish'. Over the past quarter, 4 analysts have provided ratings, with recent updates showing an increase in price targets, indicating a positive outlook on the stock. The average 12-month price target is now $34.25, up from $30.33, with JP Morgan and Baird analysts adjusting their targets upwards. The company's financial performance shows strong profitability and asset utilization, with a notable ROE of 60.47% and ROA of 3.29%, despite a high debt-to-equity ratio of 7.76.

Portfolio Pulse from Benzinga Insights

April 15, 2024 | 1:00 pm

HOOK

RHHBY

RPTX

Roche Holdings AG announced positive Phase 3 results for its lymphoma drug Columvi in combination with chemotherapy, showing extended survival in pretreated patients with diffuse large B-cell lymphoma. The study met its primary endpoint of overall survival. Columvi, a bispecific antibody, previously received FDA accelerated approval for this patient group after two or more lines of systemic therapy. Additionally, Roche terminated two cancer drug deals earlier this year with Repare Therapeutics and HOOKIPA Pharma.

Portfolio Pulse from Vandana Singh

April 15, 2024 | 12:56 pm

ONVO

Organovo shares surged following the announcement of positive Phase 2 results for FXR314, showing a significant reduction in liver fat content compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:50 pm

RVPH

Reviva Pharmaceuticals (NASDAQ:RVPH) reported Q4 losses of $(0.35) per share, missing the consensus estimate of $(0.32) by 9.37%. This represents a 7.89% improvement over the $(0.38) per share loss from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:50 pm

CRM

Salesforce Inc (CRM) shares are trading lower following reports of talks to acquire Informatica. The potential acquisition price is reportedly below Informatica's current share price. Informatica has seen a 35% increase in share price since the start of the year, following its public re-listing in 2021 after being taken private in 2015. Salesforce's earnings growth and valuation metrics, such as a compressed price to earnings ratio compared to last year and its sector peers, are also highlighted.

Portfolio Pulse from Adam Eckert

April 15, 2024 | 12:48 pm

MRNS

Marinus Pharmaceuticals shares are trading lower following an update on the Phase 3 RAISE trial and preliminary Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:46 pm

GS

LGVN

ONVO

Goldman Sachs (GS) shares rose after reporting Q1 earnings surpassing expectations. Longeveron (LGVN) surged as its Alzheimer's treatment trial will be featured at the 2024 AAIC. Organovo (ONVO) jumped on positive Phase 2 results for its liver treatment FXR314.

Portfolio Pulse from ryanfaloona@benzinga.com

April 15, 2024 | 12:44 pm

C

GS

JPM

Goldman Sachs Group Inc. (GS) reported a Q1 2024 revenue of $14.21 billion, surpassing the $12.92 billion consensus, with a 28% profit increase to $4.13 billion. This growth was driven by a 32% increase in investment banking fees and strong performance in Global Banking & Markets, Asset & Wealth Management, and FICC. Unlike its peers JPMorgan Chase & Co (JPM) and Citigroup Inc (C), which also reported strong results, Goldman Sachs primarily relies on Wall Street activities, benefiting from market booms. GS shares rose 4.04% in premarket trading.

Portfolio Pulse from Vandana Singh

April 15, 2024 | 12:43 pm

UUP

Retail sales in March 2024 rose by 4% year-over-year and 0.7% month-over-month, surpassing expectations and indicating strong consumer spending despite inflation. Nonstore retailers and gas stations saw the largest increases, while sporting goods and clothing stores experienced declines. The S&P 500 futures rose 0.8% in premarket trading, and the Invesco DB USD Index Bullish Fund ETF (UUP) gained following the report, amidst rising Treasury yields.

Portfolio Pulse from Piero Cingari

April 15, 2024 | 12:42 pm

ICCM

IceCure Medical announced the final results of its ICE3 breast cancer cryoablation trial, submitting data to the FDA for marketing authorization to treat early-stage breast cancer. The data, presented at the ASBrS Annual Meeting and awarded the Scientific Impact Award, supports the use of cryoablation for early stage T1 invasive breast cancer with adjuvant hormone therapy. The company anticipates enhanced usage upon approval, citing the availability of a reimbursement code for facility expenses and the cost-effectiveness of its ProSense® cryoablation system.

Portfolio Pulse from Benzinga Newsdesk

April 15, 2024 | 12:37 pm